---
title: "BCTXZ.US (BCTXZ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCTXZ.US/news.md"
symbol: "BCTXZ.US"
name: "BCTXZ.US"
parent: "https://longbridge.com/en/quote/BCTXZ.US.md"
datetime: "2026-03-06T03:21:15.868Z"
locales:
  - [en](https://longbridge.com/en/quote/BCTXZ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCTXZ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCTXZ.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BCTXZ.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BCTXZ.US/news.md)


# BCTXZ.US (BCTXZ.US) — Related News

### [06:00 ETCambrex anuncia al profesor Song Lin como ganador del Premio Snapdragon 2025](https://longbridge.com/en/news/276325022.md)
*2026-02-19T11:08:56.000Z*
> Cambrex has announced Professor Song Lin from Cornell University as the winner of the Snapdragon 2025 Award for Innovati

### [BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included.](https://longbridge.com/en/news/273991857.md)
*2026-01-28T12:31:40.000Z*
> BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) an

### [BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer](https://longbridge.com/en/news/273989753.md)
*2026-01-28T12:30:21.000Z*
> BriaCell Therapeutics Corp. has reported tumor regression in its Phase 2 study of Bria-IMT™ for metastatic breast cancer

### [BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial](https://longbridge.com/en/news/273873397.md)
*2026-01-27T17:05:30.000Z*
> BriaCell Therapeutics Corp. has reported positive Phase 2 clinical trial results for its Bria-IMT™ regimen in metastatic

### [Stocks in Play: BriaCell Therapeutics Corp.](https://longbridge.com/en/news/273866344.md)
*2026-01-27T15:53:48.000Z*
> 10:50 AM EST - BriaCell Therapeutics Corp. : Announces new positive Phase 2 survival data highlighting multiple patients

### [BriaCell reports extended >18-47 months survival in Phase 2 metastatic breast cancer patients, with 9 cases surpassing 18 months.](https://longbridge.com/en/news/273844421.md)
*2026-01-27T12:33:12.000Z*
> Philadelphia and Vancouver, BC - On January 27, 2026, BriaCell Therapeutics Corp revealed encouraging Phase 2 survival d